Research Topics
| Karl S PeggsSummaryAffiliation: University College London Country: UK Publications
| Collaborators
|
Detail Information
Publications
Adoptive T cell immunotherapy for cytomegalovirusKarl S Peggs
UCL Cancer Institute, Department of Haematology, Paul O Gorman Building, 72 Huntley Street, London WC1E 6BT, UK
Expert Opin Biol Ther 9:725-36. 2009....- Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantationKarl S Peggs
Department of Haematology, UCL Medical School, University College London, London, United Kingdom
Clin Infect Dis 49:1851-60. 2009.... - Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphomaKarl S Peggs
Department of Haematology, UCL Cancer Institute, Paul O Gorman Building, University College London, 72 Huntley St, London WC1E 6BT United Kingdom
J Clin Oncol 29:971-8. 2011..We aimed to assess the impact of donor lymphocyte infusions (DLIs) on relapse incidence when administered for mixed chimerism and their utility as salvage therapy when given for relapse... - HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioningAdam J Mead
Department of Haematology, University College London UCL Medical School, London, United Kingdom
Blood 115:5147-53. 2010..44). Mismatch occurred at the antigenic level in 40 cases. The outcome in these cases did not differ significantly from the rest of the cohort. We conclude that RIT using HLA-mismatched grafts is a viable option using FMC conditioning... - T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphomaKirsty J Thomson
Department of Haematology, University College Hospital, London, UK
J Clin Oncol 28:3695-700. 2010..Thus, reduced-intensity conditioning regimens are being explored... 
High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphomaAdrian J C Bloor
Department of Haematology, Royal Free and University College London School of Medicine, London, United Kingdom
Biol Blood Marrow Transplant 14:50-8. 2008..These data support the existence of a clinically significant graft-versus-tumor effect in indolent NHL and suggest that this is an effective treatment for progressive disease after allogeneic SCT...- Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activityKarl S Peggs
Department of Haematology, University College London Hospitals, London, United Kingdom
Biol Blood Marrow Transplant 9:257-65. 2003..Attempts to hasten immune reconstitution and to focus and amplify appropriate components of allogeneic T-cell responses will be required to increase complete remission rates and response durations... - Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphomaKirsty J Thomson
Royal Free and UniversityCollege Medical School, Guys Hospital, London, United Kingdom
J Clin Oncol 27:426-32. 2009.... - Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomesKarl S Peggs
Department of Haematology, Royal Free and University College, London, UK
Br J Haematol 139:70-80. 2007.... - Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapyKarl S Peggs
Department of Haematology, Royal Free and University College London Medical School, London, United Kingdom
Hum Immunol 65:550-7. 2004..This simple in vitro methodology should allow widespread application of adoptive transfer of virus-specific T cells... - Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failureSajir G Mohamedbhai
Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK
Br J Haematol 156:516-22. 2012.... - Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responsesKarl S Peggs
Department of Haematology, University College Hospital, 98 Chenies Mews, London, WC1E 6HX, United Kingdom
Blood 103:1548-56. 2004.... - Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infectionKarl S Peggs
Department of Haematology, University College London, London, United Kingdom
Biol Blood Marrow Transplant 9:198-205. 2003.... - Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphomaJonathan R Lambert
Department of Haematology, University College London Cancer Institute, London, UK
Blood 115:2763-8. 2010.... - The role of allogeneic transplantation in non-Hodgkin's lymphomaKarl S Peggs
Department of Haematology, Royal Free and University College London Medical Schools, London, UK
Br J Haematol 128:153-68. 2005.... - Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantationClaire Roddie
UCL Cancer Institute, Department of Haematology, Paul O Gorman Building, 72 Huntley Street, London, WC1E 6BT, UK
Expert Opin Biol Ther 11:473-87. 2011..The new challenge in transplantation is to optimize DLI therapy in order to further improve patient outcomes... - Allogeneic transplantation for Hodgkin lymphomaKarl S Peggs
Department of Haematology, University College London Cancer Institute, London, UK
Br J Haematol 143:468-80. 2008..This review focuses on evaluating recent experience with reduced intensity allogeneic approaches in HL in order to inform opinion on its current role and to highlight areas for future investigation... - Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantationKarl S Peggs
Department of Haematology, University College London Medical School, University College London, London, United Kingdom
Clin Infect Dis 52:49-57. 2011..The logistics of producing virus-specific T cells has, however, limited the application of cellular therapies, particularly following the introduction of more-recent regulatory stipulations... - Therapeutic strategies for the prevention and treatment of cytomegalovirus infectionRob S Sellar
UCL Cancer Institute, Department of Haematology, WC1E 6BT, London, UK
Expert Opin Biol Ther 12:1161-72. 2012..Clinical trials will help define the role of these cellular products, which have the potential to alter our entire approach to the treatment of CMV infection... - Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effectsShirley D'Sa
Department of Haematology, University College London Hospitals NHS Trust, London, UK
Br J Haematol 125:756-65. 2004..We conclude that ESHAP has acceptable toxicity and efficient stem cell mobilizing capability, effectively cytoreduced this chemoresistant group of patients, and did not appear to adversely affect transplant outcome... - Improving cellular therapies in Epstein - Barr virus-associated Hodgkin's lymphoma: shifting the equilibrium between effectors and regulatorsKarl S Peggs
Department of Haematology, Royal Free and University College London Medical Schools, London, UK
Leuk Lymphoma 47:787-9. 2006 - Management of multidrug-resistant viruses in the immunocompromised hostRob S Sellar
Department of Haematology, University College London Cancer Institute, 72 Huntley Street, London WC1E 6DD, UK
Br J Haematol 156:559-72. 2012..We also outline some of the newer agents and treatment strategies being developed to treat multidrug-resistant viruses... - Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanomaKarl S Peggs
Department of Haematology, UCL Cancer Institute, Paul O Gorman Building, University College London, 72 Huntley Street, London, WC1E 6BT, UK
Expert Rev Anticancer Ther 10:1697-701. 2010.... - Adoptive cellular therapy: a therapeutic reality?Karl S Peggs
Department of Haematology, University College Hospital, London, UK
Hematology 7:127-36. 2002..This review summarizes these developments and highlights some of the issues that remain to be resolved... - Assessing diversity: immune reconstitution and T-cell receptor BV spectratype analysis following stem cell transplantationKarl S Peggs
Department of Haematology, University College London, London, UK
Br J Haematol 120:154-65. 2003..The novel and objective diversity scoring system described appears better able to document changes in spectratype patterns than previously described techniques and should aid the standardization of reporting... - The role of virus-specific adoptive T-cell therapy in hematopoietic transplantationRob S Sellar
Department of Haematology, University College London, London, UK
Cytotherapy 14:391-400. 2012.... - Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapyKarl S Peggs
Department of Haematology, UCL Cancer Institute, University College London, London, UK
Immunol Rev 224:141-65. 2008.... - Immune reconstitution following stem cell transplantationKarl S Peggs
Department of Haematology, University College London Hospitals, London, UK
Leuk Lymphoma 45:1093-101. 2004..This review focuses mainly on recent advances in the understanding of immune reconstitution in the allogeneic setting... - Immune reconstitution following haematopoietic stem cell transplantationKarl S Peggs
Department of Haematology, University College London Hospitals, London, UK
Br J Haematol 124:407-20. 2004 - Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantationRob S Sellar
UCL Cancer Institute, Department of Haematology, London, WC1E 6BT, UK
Future Oncol 8:1549-65. 2012.... - PD-1 blockade: promoting endogenous anti-tumor immunityKarl S Peggs
Department of Haematology, UCL Cancer Institute, Paul O Gorman Building, University College London, 72 Huntley Street, London WC1E 6BT, UK
Expert Rev Anticancer Ther 12:1279-82. 2012..After a long wait, it finally seems that immune-based anticancer therapies are emerging to become part of the mainstream...